

"Express Mail" Label No. EV 330860085US
Date of Deposit February 2, 2004

PATENT
Attorney Docket No.: 018512-003814US

This is being deposited with the United States Postal Service "Express Mail
Post Office to Address" service under 37 CFR 1.10 on the date indicated
above and is addressed to:

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Grant Andrew McNaughton-
Smith, et al.

Continuation of Application
No.: 10/004,122

Filed: November 1, 2001

For: BENZANILIDES AS POTASSIUM
CHANNEL OPENERS

Examiner: Davis, Z.

Art Unit: 1625

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 10/004,122, filed 11/01/01 (Attorney Docket No. 018512-003813US) and Application No. 09/632,576, filed August 4, 2000 (Attorney Docket No. 018512-003810US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kenneth E. Jenkins".

Kenneth E. Jenkins, Ph.D.
Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KEJ:kad
60095079 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	Continuation of 10/004,122	
			Filing Date	November 1, 2001	
			First Named Inventor	McNaughton-Smith, Grant A.	
			Art Unit	1625	
Examiner Name	Davis, Z.				
Sheet	1	of	2	Attorney Docket Number	018512-003814US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US 5,466,698 A	11/14/1995	Glase, <i>et al.</i>	
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AF	DE	2343787	A1	03-21-1974	Sterling Drug Co.		<input type="checkbox"/>
	AG	JP	57-131719	A2	08-14-1982	Chugai Pharm.		
	AH	JP	57-206661		12-18-1982	Chugai Pharm.		<input type="checkbox"/>
	AI	JP	58-069812	A2	04-26-1983	Chugai Pharm.		
	AJ	JP	181257	A2	10-15-1984	Chugai Pharm.		
	AK	DE	3305569	A1	08-23-1984	Bayer, A.G.		<input type="checkbox"/>
	AL	JP	59-175467	A2	10-04-1984	Chugai Pharm.		<input type="checkbox"/>
	AM	DE	3804346	A1	08-24-1989	Boehringer Mannheim GmbH		<input type="checkbox"/>
	AN	JP	10-259176		12-09-1998	Eli Lilly and Co.		<input type="checkbox"/>
	BA	EP	882,726	A1	12-09-1998	Eli Lilly and Co.		<input type="checkbox"/>
	BB	WO	98/37068	A1	08-27-1998	Bristol-Myers Squibb		<input type="checkbox"/>
	BC	WO	98/42672	A1	10-01-1998	Kyowa Hakko Kogyo Co. Ltd.		
	BD	WO	99/05113		02-04-1999	BYK Gulden Lomberg Chemische Fabrik GMBH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60095079 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	Continuation of 10/004,122	
			Filing Date	November 1, 2001	
			First Named Inventor	McNaughton-Smith, Grant A.	
			Art Unit	1625	
			Examiner Name	Davis, Z.	
Sheet	2	of	2	Attorney Docket Number	018512-003814US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BE	Arakida, <i>et al.</i> "Binding of YM158, a new Dual Antagonist for Leukotriene D ₄ and Thromboxane A ₂ Receptors, to Guinea Pig Lung Membranes" <i>European Journal of Pharmacology</i> (1998) Vol. 362, pp. 229-233.	
	BF	Sawanishi, <i>et al.</i> "Studies on Diazepines, XXVI. Synthesis of 6H-1,4-diazepines and 1-Acyl-1-H-1,4-diazepines from 4-pyridyl azides" <i>Chem. Pharm. Bull.</i> (August 1987) Vol. 35(8), pp. 3175-3182.	
	BG		
	BH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.